|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
DK0495421T3
(da)
|
1991-01-15 |
1996-12-09 |
Alcon Lab Inc |
Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
ES2128544T3
(es)
|
1992-12-17 |
1999-05-16 |
Pfizer |
Pirrolopirimidinas como antagonistas del crf.
|
|
JPH0971528A
(ja)
*
|
1995-07-05 |
1997-03-18 |
Hayashibara Biochem Lab Inc |
抗腫瘍剤
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
WO1997029109A1
(en)
|
1996-02-07 |
1997-08-14 |
Janssen Pharmaceutica N.V. |
Pyrazolopyrimidines as crf receptor antagonists
|
|
WO1997030035A1
(en)
|
1996-02-13 |
1997-08-21 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
|
ES2169355T3
(es)
|
1996-03-05 |
2002-07-01 |
Astrazeneca Ab |
Derivados de 4-anilinoquinazolina.
|
|
HU229024B1
(en)
|
1996-07-24 |
2013-07-29 |
Bristol Myers Squibb Pharma Co |
Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
|
|
TR199900389T2
(xx)
|
1996-08-28 |
2000-06-21 |
Pfizer Inc. |
�kame edilmi� 6,5-hetero-bisiklik t�revleri.
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
IL137019A
(en)
|
1998-01-28 |
2010-11-30 |
Du Pont Pharm Co |
2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
EP1040831A3
(en)
|
1999-04-02 |
2003-05-02 |
Pfizer Products Inc. |
Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
|
|
AU4203500A
(en)
|
1999-04-06 |
2000-10-23 |
Du Pont Pharmaceuticals Company |
Pyrazolopyrimidines as crf antagonists
|
|
FR2796380B3
(fr)
|
1999-07-15 |
2001-08-17 |
Sanofi Synthelabo |
Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
|
|
YU23602A
(sh)
|
1999-09-30 |
2004-09-03 |
Neurogen Corporation |
Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
|
|
CA2362816C
(en)
|
1999-12-08 |
2007-02-06 |
Pharmacia Corporation |
Valdecoxib compositions
|
|
IL152682A0
(en)
|
2000-05-31 |
2003-06-24 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
|
BR0112224A
(pt)
|
2000-07-07 |
2003-06-10 |
Angiogene Pharm Ltd |
Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
|
|
HUP0301742A3
(en)
|
2000-07-07 |
2005-08-29 |
Angiogene Pharm Ltd |
Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
|
|
JP4549630B2
(ja)
|
2001-03-13 |
2010-09-22 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
|
|
US20050085479A1
(en)
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
|
WO2005053796A1
(en)
|
2003-12-02 |
2005-06-16 |
B & B Beheer Nv |
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
|
|
NZ547990A
(en)
|
2003-12-22 |
2010-04-30 |
Smithkline Beecham Cork Ltd |
CRF receptor antagonists and methods relating thereto
|
|
AU2005215257A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
|
JP2008503444A
(ja)
|
2004-02-13 |
2008-02-07 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
|
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
PT1869049E
(pt)
|
2005-03-21 |
2009-05-26 |
Lilly Co Eli |
Compostos de imidazopiridazina
|
|
WO2007109853A1
(en)
*
|
2006-03-29 |
2007-10-04 |
Velacor Therapeutics Pty Ltd |
Inorganic selenium for treatment of benign tumors
|
|
CN101516835A
(zh)
|
2006-07-19 |
2009-08-26 |
俄亥俄州立大学研究基金会 |
选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
|
|
UA96458C2
(ru)
|
2006-09-20 |
2011-11-10 |
Эли Лилли Энд Компани |
Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
|
|
CA2662000C
(en)
|
2006-09-20 |
2013-01-08 |
Eli Lilly And Company |
Thiophene pyrazolopyrimidine compounds
|
|
US8952207B2
(en)
|
2007-09-11 |
2015-02-10 |
The University Of Houston System |
Copper-catalyzed C—H bond arylation
|
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
|
US20100203048A1
(en)
*
|
2008-04-30 |
2010-08-12 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the use of the treatment of cancer
|
|
TWI432435B
(zh)
|
2008-10-02 |
2014-04-01 |
Lilly Co Eli |
作為合成中間物之噻唑基－吡唑并嘧啶化合物及相關合成方法
|
|
US8153962B2
(en)
|
2008-12-24 |
2012-04-10 |
Quest Diagnostics Investments Incorporated |
Mass spectrometry assay for congenital adrenal hyperplasia
|
|
PL2519230T3
(pl)
|
2009-12-31 |
2019-05-31 |
Marius Pharmaceuticals Llc |
Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
|
|
AU2013230781B2
(en)
|
2012-03-08 |
2015-12-03 |
Medtronic Af Luxembourg S.A.R.L. |
Ovarian neuromodulation and associated systems and methods
|
|
JP2015516979A
(ja)
|
2012-04-23 |
2015-06-18 |
ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ |
Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
|
|
JP6585625B2
(ja)
*
|
2014-01-21 |
2019-10-02 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
|
|
ES2964948T3
(es)
|
2015-03-31 |
2024-04-10 |
May Health Us Inc |
Métodos y sistemas para la manipulación de tejidos ováricos
|
|
KR20250022913A
(ko)
|
2017-08-14 |
2025-02-17 |
스프루스 바이오사이언시스 인코포레이티드 |
코티코트로핀 방출 인자 수용체 길항제
|
|
MX2019015318A
(es)
|
2017-08-14 |
2020-07-20 |
Spruce Biosciences Inc |
Antagonistas del receptor del factor liberador de corticotropina.
|
|
CN112423747A
(zh)
|
2018-04-27 |
2021-02-26 |
云杉生物科学公司 |
用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
|
|
MA54395A
(fr)
|
2018-12-07 |
2022-03-16 |
Neurocrine Biosciences Inc |
Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
|
|
US20200255436A1
(en)
|
2019-02-12 |
2020-08-13 |
Spruce Biosciences, Inc. |
Corticotropin releasing factor receptor antagonists
|
|
TW202116324A
(zh)
|
2019-07-19 |
2021-05-01 |
美商雲杉生物科技股份有限公司 |
治療先天性腎上腺增生之方法
|
|
MX2023001688A
(es)
|
2020-08-12 |
2023-02-22 |
Spruce Biosciences Inc |
Metodos y composiciones para tratar el sindrome de ovario poliquistico.
|
|
WO2023091684A1
(en)
|
2021-11-19 |
2023-05-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|
|
US11708372B2
(en)
|
2021-11-19 |
2023-07-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|